secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001437749-23-012844
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech receives Nasdaq deficiency notice for bid price below $1.00; compliance deadline Nov 1, 2023
--------------------------------------------------------------------------------

- Received Nasdaq deficiency letter on May 5, 2023 for failing minimum $1.00 bid price for 30 consecutive days.
- Has 180 days until November 1, 2023 to regain compliance by closing at $1.00+ for at least 10 business days.
- If non-compliant by Nov 1, may qualify for second 180-day period if meets other listing standards.
- Company may consider a reverse stock split to cure deficiency, but no assurance of success.
- No immediate delisting; can appeal any delisting determination to a Nasdaq Listing Qualifications Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923012844/0001437749-23-012844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923012844/mbrx20230505_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-012844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer